ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2264

Dysregulated Interferon Gamma Signals Promote Systemic Autoimmunity in STAT1 Gain of Function Syndrome

Andrea Largent1, Jane Buckner2, David Rawlings1 and Shaun Jackson1, 1Seattle Children's Research Institute, Seattle, WA, 2Benaroya Research Institute at Virginia Mason, Seattle, WA

Meeting: ACR Convergence 2022

Keywords: Animal Model, autoimmune diseases, cytokines, interferon

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: Abstracts: SLE – Etiology and Pathogenesis

Session Type: Abstract Session

Session Time: 5:00PM-6:00PM

Background/Purpose: Heterozygous gain-of-function mutations in STAT1 promote a complex disorder of immune dysregulation including chronic mucocutaneous candidiasis (CMC) and systemic autoimmunity. However, given widespread expression of STAT1 in immune and non-immune lineages and engagement by multiple cytokine receptors, the immune mechanisms driving breaks in immune tolerance in STAT1 GOF syndrome remain poorly understood.

Methods: We performed multiparameter immunophenotyping of peripheral blood mononuclear cells (PBMCs) from 8 pediatric STAT1 GOF patients and 9 age-matched controls. Affected subjects were studied prior to treatment with JAK inhibitors, allowing unique insight into the immune landscape of STAT1-driven immune dysregulation. In parallel, we generated a novel murine knock-in strain allowing cell-intrinsic expression of a pathogenic human STAT1 GOF mutation.

Results: We performed deep immunophenotyping of pediatric STAT1 GOF patients and age-matched controls to identify immune characteristics of STAT1-driven inflammation. Affected patients exhibited dysregulated CD4+ T cell and B cell activation which correlated with serum autoantibody titers. In the parallel murine model, Stat1 GOF transgenic mice, which developed spontaneous humoral autoimmunity recapitulating the human phenotype. Despite clinical resemblance to human regulatory T cell (Treg) deficiency (IPEX syndrome), Stat1GOF mice and humans exhibited normal Treg development and function. Rather, STAT1 GOF autoimmunity was driven by dysregulated STAT1-dependent signals downstream of the type 1 and type 2 interferon (IFN) receptors. Surprisingly, autoimmunity in Stat1GOF mice lacking the type 1 IFN receptor (IFNAR) was only partially ameliorated, whereas loss of type 2 IFN (IFN-γ) signals prevented disease. Strikingly, IFN-γR deletion abolished the known increase in total STAT1 expression in STAT1 GOF syndrome resulting in normalization of STAT1-dependent systemic inflammation. Since STAT1 regulates its own transcription, these findings highlight IFN-γ as the critical driver of a feedforward inflammatory cascade in STAT1 GOF syndrome.

Conclusion: Human genetic variations resulting in immunodeficiency and/or the propensity for autoimmunity represent “experiments of nature” that can advance our understanding of the human immune system and may inform the development of targeted therapies for inflammatory disease. Our data provide new insights into the STAT1-dependent cellular mechanisms underlying both rare monogenic and more common polygenic autoimmune diseases, such as systemic lupus erythematosus.


Disclosures: A. Largent, None; J. Buckner, Amgen, Bristol Myers Squibb, Gentiobio, Hot Spot Therapeutics, Janssen, Pfizer, Novo Nordisk, Allen Institute for Immunology, Type 1 Diabetes TrialNet Study Group, La Jolla Institute, Oklahoma Medical Research Foundation, Bristol Myers Squibb Immunology, Colton Center for Autoimmunity at Penn, Board of Scientific Counsellors; D. Rawlings, None; S. Jackson, None.

To cite this abstract in AMA style:

Largent A, Buckner J, Rawlings D, Jackson S. Dysregulated Interferon Gamma Signals Promote Systemic Autoimmunity in STAT1 Gain of Function Syndrome [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/dysregulated-interferon-gamma-signals-promote-systemic-autoimmunity-in-stat1-gain-of-function-syndrome/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dysregulated-interferon-gamma-signals-promote-systemic-autoimmunity-in-stat1-gain-of-function-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology